title: Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.
abstract: BACKGROUND
  Animal studies have demonstrated that an inhibition of DPP-4 has an impact on the secretion of cholesterol and apoB by the small intestine. However, there is no consensus about the changes of the lipid profile following administration of sitagliptin.
  
  
  METHODS
  Accordingly, we treated patients who had type 2 diabetes complicated by dyslipidemia with sitagliptin and evaluated its effects on the profile of lipid parameters. A total of 248 outpatients with type 2 diabetes complicated by dyslipidemia were treated with sitagliptin at a daily dose of 50 mg. The levels and percent changes of lipid and glucose metabolism markers were measured at baseline and at 12 weeks after the initiation of treatment.
  
  
  RESULTS
  Both plasma glucose and HbA1c were significantly decreased. Among the lipid parameters, total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) showed a significant decrease (TC 3.6±15.6%, non-HDL-C 2.9±19.7%; P < 0.05). Stratified analysis revealed a significant decrease of TC, low-density lipoprotein cholesterol (LDL-C) and non-HDL-C in the high triglyceride (TG) group (≥ 150 mg/dL) (P < 0.05). Analysis stratified by demographic factors demonstrated significant differences in the changes of TC, LDL-C and non-HDL-C. Multivariate analysis showed a significant decrease of the TC, LDL-C and non-HDL-C levels in the high TG group (≥ 150 mg/dL), as well as a significant decrease of TC and LDL-C in patients using strong statins.
  
  
  CONCLUSIONS
  The results suggested that sitagliptin caused a significant decrease of TC, LDL-C and non-HDL-C, particularly in patients with high baseline TG levels and those using strong statins.
authors.affiliation: Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Erina
authors.initials: E
authors.lastname: Shigematsu
authors.affiliation: Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yamakawa
authors.affiliation: Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
authors.affiliation: Department of Endocrinology and Metabolism, Yokohama City University School of Medicine, Yokohama, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
keywords: LDL cholesterol; Non-HDL cholesterol; Sitagliptin; Total cholesterol
references.citation: J Neurosci. 2009 May 6;29(18):5916-25
references.pmid: 19420258
references.citation: Expert Opin Investig Drugs. 2008 Jan;17(1):105-13
references.pmid: 18095923
references.citation: Adv Ther. 2012 Jan;29(1):14-25
references.pmid: 22215383
references.citation: Pharmacol Res. 2005 Jan;51(1):31-6
references.pmid: 15519532
references.citation: Diabetes Care. 1988 Nov-Dec;11(10):794-5
references.pmid: 3073069
references.citation: J Clin Invest. 2000 Aug;106(4):453-8
references.pmid: 10953019
references.citation: Diabetes Care. 2003 Oct;26(10):2929-40
references.pmid: 14514604
references.citation: Cardiovasc Diabetol. 2013 Feb 21;12:35
references.pmid: 23432786
references.citation: Diabetologia. 1994 Aug;37(8):781-7
references.pmid: 7988780
references.citation: J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66
references.pmid: 21558879
references.citation: Diabetes Care. 2008 Feb;31 Suppl 2:S241-8
references.pmid: 18227492
references.citation: J Manag Care Pharm. 2006 Sep;12(7 Suppl A):S2-12; quiz S14-6
references.pmid: 16981805
references.citation: Diabetes Care. 2007 Feb;30(2):217-23
references.pmid: 17259484
references.citation: Diabetes Obes Metab. 2008 Sep;10(10):959-69
references.pmid: 18201203
references.citation: Metabolism. 2004 Feb;53(2):159-64
references.pmid: 14767866
references.citation: J Med Chem. 2005 Jan 13;48(1):141-51
references.pmid: 15634008
references.citation: Nature. 2001 Dec 13;414(6865):782-7
references.pmid: 11742409
references.citation: Diabetes Care. 2006 Dec;29(12):2638-43
references.pmid: 17130197
references.citation: Diabetes Care. 1994 Oct;17(10):1093-9
references.pmid: 7821127
references.citation: J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9
references.pmid: 16912128
references.citation: Endocr J. 2013;60(7):913-22
references.pmid: 23574730
references.citation: Diabetologia. 2010 Mar;53(3):552-61
references.pmid: 19957161
references.citation: J Clin Med Res. 2012 Oct;4(5):309-13
references.pmid: 23024732
references.citation: Diabetes Obes Metab. 2013 May;15(5):455-62
references.pmid: 23279373
references.citation: Diabetes Care. 1990 Feb;13(2):153-69
references.pmid: 2190770
references.citation: N Engl J Med. 1995 Jun 1;332(22):1491-8
references.pmid: 7739687
references.citation: J Diabetes Investig. 2010 Oct 19;1(5):212-28
references.pmid: 24843435
references.citation: Diabetologia. 2006 Sep;49(9):2049-57
references.pmid: 16816950
references.citation: Diabetes Obes Metab. 2011 Apr;13(4):366-73
references.pmid: 21226820
references.citation: Diabetologia. 2006 Mar;49(3):452-8
references.pmid: 16447057